5-(三氟甲氧基)-1H-吲哚-2-羧酸乙酯 | 175203-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-(三氟甲氧基)-1H-吲哚-2-羧酸乙酯
• 中文别名: 5-三氟甲氧基-吲哚-2-羧酸乙酯；5-三氟甲氧基-1H-吲哚-2-羧酸乙酯
• 英文名称: ethyl 5-(trifluoromethoxy)-1H-indole-2-carboxylate
• CAS: 175203-82-4
• 化学式: C₁₂H₁₀F₃NO₃
• 分子量: 273.212
• InChiKey: LLGKTDNPBIFJKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  144 °C
• 沸点：
  339.9±37.0 °C(Predicted)
• 密度：
  1.389±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 储存条件：
  室温

SDS

Name:	Ethyl 5-(trifluoromethoxy)-1H-indole-2-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	175203-82-4

Section 1 - Chemical Product MSDS Name:Ethyl 5-(trifluoromethoxy)-1H-indole-2-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175203-82-4	Ethyl 5-(trifluoromethoxy)-1H-indole-2	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175203-82-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H10F3NO3
Molecular Weight: 273

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175203-82-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 5-(trifluoromethoxy)-1H-indole-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 175203-82-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175203-82-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175203-82-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(三氟甲氧基)-1H-吲哚-2-羧酸乙酯 在 sodium tetrahydroborate 、 sodium hydride 、 cobalt(II) chloride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 16.5h， 生成
  参考文献：
  名称：

  Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer

  摘要：

  Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping. Structure-activity relationship studies led to the discovery of compound 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line. Further antitumor mechanism studies indicated that compound 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest. The quaternary ammonium salt of compound 15j (compound 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity. Indolopyrazinoquinazolinone derivatives represent promising multitargeting antitumor leads for the development of novel antitumor agents.

  DOI：

  10.1021/acs.jmedchem.9b01626
• 作为产物：
  描述：

  丙酮酸乙酯 、 对三氟甲氧基苯胺 在 氧气 、 palladium diacetate 、 溶剂黄146 作用下， 以 二甲基亚砜 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以60%的产率得到5-(三氟甲氧基)-1H-吲哚-2-羧酸乙酯
  参考文献：
  名称：

  通过有氧交叉脱氢偶联从简单的苯胺和酮中羧酸促进的一步吲哚构建

  摘要：

  交叉脱氢偶联（CDC）反应是吲哚合成的有效策略。但是，大多数CDC方法需要特殊的底物，并且固有基团的存在限制了进一步转化的通用性。本文开发了一种羧酸促进的需氧催化系统，用于由简单的苯胺和酮一步合成吲哚。这种多功能的系统具有广泛的底物范围和使用环境氧气作为氧化剂的特点，对于实验室和工业应用均既方便又经济。C-3上不稳定的氢和C-2上高度可转化的羰基的存在，使吲哚在各种情况下成为有机合成的通用结构单元。基于密度泛函理论（DFT）的计算研究表明，决定速率的步骤是底物的羧酸辅助缩合，而不是芳基CH的官能化。因此，经由亚胺中间体的途径被认为是优选的机制。与一般的推论相反，据信原位形成的亚胺代替其烯胺异构体参与了α-Me的首次配体交换和随后的碳pal化，这为这种吲哚化机理提供了新的思路。

  DOI：

  10.1021/acs.joc.8b02180

文献信息

• [EN] SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'INDOLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：SCHERING CORP

  公开号：WO2009032124A1

  公开（公告）日：2009-03-12

  The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

  本发明涉及取代吲哚衍生物，包括至少一种取代吲哚衍生物的组合物，以及利用这些取代吲哚衍生物治疗或预防患者病毒感染或与病毒相关的疾病的方法。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2014068988A1

  公开（公告）日：2014-05-08

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑并吡啶衍生物，这些衍生物具有阻断TTX-S型电压门控钠通道的活性，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
• Tripeptidyl peptidase inhibitors
  申请人：Institut National de la Sante et de la Recherche Medicale (INSERM)

  公开号：US06335360B1

  公开（公告）日：2002-01-01

  The invention is relative to a compound of formula (I) and its use as an inhibitor of the CCK-inactivating peptidase tripeptidyl peptidase (TPP II). The invention concerns in particular the treatment of eating disorder, obesity, psychotic syndrome and associated psychiatric disorders. It concerns also the cosmetic use of a compound (I) in particular to aid slimming.

  这项发明涉及一种化合物的公式(I)，以及其作为CCK失活肽酶三肽肽酶(TPP II)的抑制剂的用途。该发明特别涉及治疗进食障碍、肥胖、精神症候群及相关精神障碍。还涉及一种化合物(I)的化妆用途，特别是用于辅助减肥。
• 一种2-取代吲哚衍生物的合成方法
  申请人：中国医学科学院药物研究所

  公开号：CN109748840B

  公开（公告）日：2021-12-07

  本发明涉及一种制备2‑取代吲哚衍生物的合成方法，将芳香胺类化合物(I)，酮类化合物(II)和干燥剂在有机溶剂中混合，加入钯类催化剂后在有氧的弱酸性环境下反应制得所述吲哚类化合物(III)，(I)为(II)为(III)为其中R1选自氢、C1‑C6烷基、C1‑C6烷氧基、C1‑C6烷酰基、C2‑C6烯基、C2‑C6炔基、卤素、羟基、取代或未取代的氨基、取代或未取代的苯基及吡啶基及杂环芳基；(I)也可以取代或未取代的吡啶胺、嘧啶胺、哒嗪胺或吡嗪胺；取代基选自一个或多个C1‑C6烷基、C1‑C6烷氧基、C1‑C6烷酰基、C2‑C6烯基、C2‑C6炔基、卤素、羟基、氨基；R2选自C1‑C6烷基、甲酸酯基或C1‑C6烷酰胺基。
• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Bolin David Robert

  公开号：US20100145047A1

  公开（公告）日：2010-06-10

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。